Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy.
Sci Transl Med. 2020 Jun 24;12(549):eaba2325. doi: 10.1126/scitranslmed.aba2325.
Sci Transl Med. 2020.
PMID: 32581132